| 摘要 |
<P>PROBLEM TO BE SOLVED: To provide a new treating agent for treating cancer and a new more effective combination of treating methods for treating the cancer. <P>SOLUTION: The uses of EphA2 monoclonal antibody are provided by comprising the administration of an effective amount of an antibody bonding with and acting to the EphA2, and thereby increasing the phosphorylation of the EphA2 to reduce an EphA2 level, also comprising the administration of an effective amount of the antibody bonding with the EphA2, inhibiting the colony formation of the cancer cells in soft agar, inhibiting a tubular network formation in a three-dimensional base membrane or an extracellular matrix preparation, binding preferentially with the epitope of the EphA2, exposed on the cancer cells and not with non-cancer cells, and/or having a low K<SB>off</SB>, and thereby inhibiting the propagation and/or metastasis of the cancer cells, and further comprising the administration of a medicinal composition containing the EphA2 antibody singly or combined with one kind or a plurality of other medicines useful for the treatment of the cancer. <P>COPYRIGHT: (C)2011,JPO&INPIT |
